The Biden administration has proposed expanding Medicare and Medicaid to cover popular weight-loss medications like Wegovy and Zepbound, recognizing obesity as a treatable disease. These medications help reduce weight by 15-25%, potentially lowering risks for heart disease and diabetes.

If approved, this change could cut the cost of these pricey drugs (often over $1,000/month) by 95% for 7.4 million beneficiaries, but it’s projected to cost taxpayers $35 billion over a decade.

The rule isn’t final yet and could face changes under the incoming Trump administration, as HHS nominee Robert F. Kennedy Jr. has voiced skepticism about drugmakers and favors focusing on access to healthy nutrition.

"I do not share this to express support or opposition to the proposal. My considerations include improved and equitable access to medical treatments, use of taxpayer dollars, prioritizing systemic solutions for obesity over medication, and ensuring patient suitability. In my practice, I’ve observed that Medicare and Medicaid patients often have more complex medical needs and take multiple medications. These weight-loss drugs can affect how other medications work, necessitating frequent monitoring and dosage adjustments. Additionally, some geriatric patients tolerate GLP-1 and GIP weight-loss drugs poorly and experience more side effects. These are important factors to consider."

https://www.cnbc.com/2024/11/26/biden-proposes-medicare-and-medicaid-cover-weight-loss-drugs.html